Craig-Hallum analyst Chase Knickerbocker raised the firm’s price target on Phathom Pharmaceuticals (PHAT) to $22 from $17 and keeps a Buy rating on the shares. The firm notes the company delivered a solid beat on both revenue and expense discipline as the company pivots away from direct-to-consumer sales and focuses on GI specialists. FY2025 revenue guidance was raised at the midpoint to $170M-$175M from $165M-$175M, and management reiterated expectations for operating profitability in 2026.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHAT:
- Phathom Pharmaceuticals price target raised to $26 from $20 at H.C. Wainwright
- Phathom Pharmaceuticals Reports Strong Q3 2025 Growth
- Phathom Pharmaceuticals: Strong Q3 Performance and Promising Growth Drive Buy Rating
- Phathom Pharmaceuticals reports Q3 adjusted EPS (15c), consensus (41c)
- Phathom Pharmaceuticals sees cash sufficient to fund operations in 2026